Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Salmeterol/fluticasone Diskus · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Budesonide/formoterol Turbuhaler | DRUG | - |
| Salmeterol/fluticasone Diskus | DRUG | - |
Inclusion Criteria: * Diagnosed with asthma since at least 6 months prior to first visit * Prescribed daily use of glucocorticosteroids for at least 3 months prior to first visit * At least one asthma exacerbation more than one but less than twelve months prior to first visit Exclusion Criteria: ...
Salmeterol/fluticasone Diskus is used for the treatment of asthma. It is a combination product containing two active ingredients, salmeterol and fluticasone, delivered via a Diskus inhaler. The drug is being developed by AstraZeneca PLC for this respiratory condition.
Salmeterol/fluticasone Diskus is developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is conducting clinical trials to evaluate the efficacy and safety of this drug in patients with asthma.
Salmeterol/fluticasone Diskus is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug is being studied for the treatment of asthma.
Salmeterol/fluticasone Diskus has one completed Phase 3 clinical trial registered under NCT00242775. This trial compared the efficacy and safety of Salmeterol/fluticasone Diskus with other asthma treatments, enrolling 2100 patients aged 12 years and older across multiple countries.
Salmeterol/fluticasone Diskus combines two active ingredients: salmeterol, a long-acting beta-agonist that relaxes airway muscles, and fluticasone, a corticosteroid that reduces inflammation in the airways. Together, they help improve asthma control by addressing both bronchoconstriction and airway inflammation.